Iridescent

Iridescent Bio was a Dutch biotechnology company that developed an AI-powered SaaS platform for the identification and optimization of therapeutic antibodies. Founded in 2023 and headquartered in Leiden, the company integrated physics-based modeling with machine learning to predict the biophysical properties and developability of antibodies directly from their molecular structures. The platform aimed to accelerate drug discovery by mining patent literature and providing deep insights into binding affinity, target specificity, and aggregation risks. Despite securing early-stage funding from investors like UNIIQ and forming key partnerships with organizations such as The Lens, the company reportedly ceased operations in May 2025. Its technology was designed to help researchers make informed decisions early in the R&D process, potentially reducing the time and cost of laboratory screening.